First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy ; volume:7 ; number:1 ; day:3 ; month:5 ; year:2019 ; pages:1-6 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (3.5.2019), 1-6, 12.2019
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Zhou, Yixin
Lin, Zuan
Zhang, Xuanye
Chen, Chen
Zhao, Hongyun
Hong, Shaodong
Zhang, Li
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0600-6
- URN
-
urn:nbn:de:101:1-2019052702294513535821
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhou, Yixin
- Lin, Zuan
- Zhang, Xuanye
- Chen, Chen
- Zhao, Hongyun
- Hong, Shaodong
- Zhang, Li
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pembrolizumab
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Pembrolizumab for all
How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study
Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Pembrolizumab: The Nut Cracker
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
Pembrolizumab
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Pembrolizumab for all
How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study
Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Pembrolizumab: The Nut Cracker
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
Pembrolizumab
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Bronchialkarzinom – Pembrolizumab vorteilhaft bei PD-L1-positiven Patienten
Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
Pembrolizumab for all
How do behavior problems change over time in childhood? Evidence from the early childhood longitudinal study
Synthesis of Ambient Copolymerization CQAS Hydrogel Composite Membrane with Enhanced Antifouling
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Pembrolizumab: The Nut Cracker